Top Qs
Timeline
Chat
Perspective
Rociletinib
Cancelled developmental cancer drug From Wikipedia, the free encyclopedia
Remove ads
Rociletinib is a medication developed to treat non-small cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor.[1] It was being developed by Clovis Oncology as a potential treatment for non-small-cell lung cancer.[1] In May 2016, development of rociletinib was halted, along with its associated clinical trials, and Clovis Oncology withdrew its marketing authorisation application from the European Medicines Agency.[1]
Remove ads
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads